This Year's Highlights

• June 2006: ApopLogic adds Breceptin technology from University of Colorado and adds Drs. Paul A. Bunn, Daniel Chan, Lajos Gera and John Stewart as Founding Scientists.
• June 2006: ApopLogic receives Proof-of-concept investment (POC-i; $100K) from University of Colorado for pre-clinical development of Fasaret to treat glioblastoma.
• July 2006: ApopLogic receives notice of phase 1 SBIR grant award ($800K) to test Fasaret in a clinical trial in dogs with osteosarcoma.

Anticipated Highlights

• Q3 2006: Completion of licensing agreements regarding Breceptin and Apoptocides with University of Colorado
• Q4 2006 initiate GMP manufacture of Breceptin.

Corporate Mission

ApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas. The Company was established in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Drs. Richard Duke, Donald Bellgrau, Paul Bunn, Daniel Chan, Lajos Gera, Jaime Modiano, John Stewart. Put most simply, ApopLogic is inducing rapidly dividing cells to commit suicide. Diseases and conditions targeted by the Company?s products affect large patient populations and cannot be treated satisfactorily with existing therapies.

ApopLogic?s products are:

Breceptin: A novel neuropeptide growth factor receptor antagonist that targets a broad range of cancers.

Cytonil: A proprietary combination of a cell-type specific growth factor and a cell signaling agonist to treat Sezary leukemia, mycosis fungoides, and cutaneous T cell lymphoma.

Fasaret: A proprietary therapy based on Fas ligand, an apoptotic cell death-inducing molecule with unique pro-inflammatory properties, for the treatment of cancers.

Pre-clinical research studies have been completed for each of the Company?s products. Series A financing is being sought to support GMP manufacture, GLP pharmacology and toxicology studies, and phase 1 human clinical trials that could begin within 12 months of closing.

In summary, ApopLogic is an oncology drug development company with experienced scientific and management teams, broadly applicable technology, well-defined clinical development plans, and multiple exit strategies for investors.